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Abstract  A  28-year-old  man  diagnosed  with  primary  adrenal  insufﬁciency  (Addison’s  disease)
in 2002.  Following  diagnosis,  replacement  therapy  with  hydrocortisone  and  ﬂudrocortisone  was
indicated. Hydrocortisone  replacement  therapy  was  unsuccessful,  and  increased  ACTH  levels
as high  as  996  pg/dl  were  observed  on  outpatient  follow-up.  A  pituitary  MRI  revealed  a  pitu-
itary microadenoma.  These  ﬁndings  raised  three  possibilities:  (1)  treatment  is  insufﬁcient;  (2)
there is  no  relationship  between  Addison’s  disease  and  pituitary  microadenoma;  and  (3)  the
microadenoma  is  similar  to  Nelson’s  syndrome.  This  latter  is  the  most  satisfactory  explanation
of this  patient’s  clinical  picture.
© 2015  Sociedad  Médica  del  Hospital  General  de  México.  Published  by  Masson  Doyma  México
S.A. All  rights  reserved.
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Enfermedad  de  Addison  y  microadenoma  hipoﬁsario  productor  de  ACTH
Resumen  Un  varón  de  28  an˜os  fue  diagnosticado  de  insuﬁciencia  suprarrenal  primaria  autoin-
mune (enfermedad  de  Addison)  en  el  an˜o  2002.  Tras  ello,  se  indica  tratamiento  sustitutivo  con
hidrocortisona  y  ﬂudrocortisona.  En  el  seguimiento  ambulatorio  se  objetiva  un  aumento  de  los
niveles de  ACTH,  llegando  a  996  pg/dl,  con  tratamiento  sustitutivo  con  hidrocortisona  que  no
logra suprimir  la  ACTH.  Por  ello  se  realiza  RNM  de  hipóﬁsis  donde  se  objetiva  un  microadenoma
hipoﬁsario.  Ante  estos  hallazgos  se  plantearon  tres  posibilidades:  1.-  El  tratamiento  es  insuﬁ-
ciente; 2.-  No  existe  relación  entre  la  enfermedad  de  Addison  y  el  microadenoma  hipoﬁsoario;
3.- El  microadenoma  se  considera  una  situación  clínica  similar  al  síndrome  de  Nelson.  Esta  última
respuesta  es  la  que  da  una  explicación  más  satisfactoria  al  cuadro  clínico  de  este  paciente.
© 2015  Sociedad  Médica  del  Hospital  General  de  México.  Publicado  por  Masson  Doyma  México
S.A. Todos  los  derechos  reservados.∗ Corresponding author at: Urbanización El Arco, 16, La Atalaya, 35307
E-mail address: drsuarez@hotmail.com (S.S. Ortega).
http://dx.doi.org/10.1016/j.hgmx.2015.08.007
0185-1063/© 2015 Sociedad Médica del Hospital General de México. Pub Santa Brígida, Las Palmas, Spain.
lished by Masson Doyma México S.A. All rights reserved.
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ddison’s  disease  is  characterised  by  failure  of  the
drenal  glands  to  produce  sufﬁcient  steroid  hormones,
he  most  common  aetiology  being  autoimmune  adrenalitis
nd  tuberculosis.  This  causes  the  classic  signs  of  suprar-
enal  insufﬁciency,  along  with  the  melanoderma  typical  of
ncreased  adrenocorticotropic  hormone  (ACTH)  secretion.1,2
CTH  overproduction  in  response  to  decreased  cortisol  lev-
ls  can  also  be  caused  by  an  autonomously  functioning
ituitary  adenoma,  as  seen  in  Nelson’s  syndrome.3,4 The
CTH  increase  seen  in  Addison’s  disease  could  also  be
ue  to  primary  pituitary  ACTH  hypersecretion  unrelated  to
ortisolemia,5 or  to  both  of  the  foregoing  cases.  We  present
he  case  of  a  pituitary  microadenoma  in  a  patient  with  Addi-
on’s  disease  that  could  be  interpreted  as  either  Nelson’s
yndrome  or  primary  pituitary  ACTH  hypersecretion  coex-
sting  with  Addison’s  disease.  The  gradual  increase  in  ACTH
evels  despite  appropriate  replacement  therapy  with  hydro-
ortisone  would  seem  to  bear  out  the  latter  hypothesis.  This
linical  situation  could  also  be  explained  by  ACTH  hyper-
ecretion  secondary  to  adrenal  dysfunction  that  eventually
ecomes  autonomous,  as  in  tertiary  hyperparathyroidism  in
idney  failure.6
ase study
 28-year-old  man  was  admitted  to  our  hospital  in  2002  for
eriodic  paralysis,  anorexia,  weight  loss  of  8  kg  in  the  pre-
ious  12  months,  vomiting  and  general  malaise.  On  physical
xamination,  he  presented  hyperpigmentation  of  the  palms
f  the  hands,  oral  mucosa,  and  axillary  and  inguinal  folds.
rterial  pressure  was  90/60  mmHg,  heart  rate  was  96  bpm,
xillary  temperature  was  37 ◦C,  weight  62  kg  and  height
.69  cm.  Emergency  laboratory  tests  showed  hyponatraemia
128  mEq/l)  and  mild  hyperpotassaemia  (6.1  mEq/l),  slightly
levated  BUN  and  normal  creatinine.  Once  ionic  changes
ad  been  normalised,  we  measured  basal  cortisol  (less
han  1  mcg/dl)  and  ACTH  levels  (336  pg/ml,  normal  levels
p  to  50  pg/ml).  This  was  followed  by  a  prolonged  ACTH
igure  1  T1  weighted  spin  echo  sequence  with  IV  gadolinium  in  
entre of  the  anterior  pituitary.  Compatible  with  microadenoma.
l
s
s
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timulation  test,  with  no  elevation  of  cortisolaemia.  We
tarted  replacement  treatment  with  30  mg  hydrocortisone
nd  0.1  mg  ﬂudrocortisone  daily,  with  outpatient  follow-up.
ntiadrenal  antibody  levels  were  >1/20  (normal,  absent).
n  follow-up,  ACTH  levels  remained  elevated  and  did  not
espond  to  replacement  therapy,  so  this  was  increased  to
0  mg  hydrocortisone  daily.  ACTH  was  measured  every  2
ears  between  2004  and  2014,  showing  levels  of  405,  438,
10,  782,  489  and  996  pg/ml.  Prolactin,  FSH-LH,  TSH  and
GH  levels  were  normal.  Over  the  prolonged  follow-up
eriod,  the  patient  has  adhered  strictly  to  the  therapeutic
egimen  (Morisky  Green  test),  and  has  had  no  intercurrent
isease  or  need  for  hospitalisation.  On  the  basis  of  ACTH  lev-
ls,  we  decided  to  perform  a targeted  MRI  examination  of
he  pituitary  region,  which  revealed  a  cold  lesion  measuring
.5  mm,  compatible  with  a  pituitary  microadenoma  (Fig.  1).
he  long  clinical  evolution,  with  normal  ﬁndings  on  serial
ampimetry  and  imaging  studies  (chest  X-ray  and  abdomi-
al  ultrasound),  all  but  rules  out  the  coexistence  of  ectopic
CTH  secretion.
iscussion
ur  patient  meets  the  criteria  for  ACTH-secreting  pitu-
tary  adenoma,  with  no  clinical  signs  of  a  space-occupying
esion.  As  the  most  characteristic  sign  of  increased  ACTH  is
elanodermia,  we  decided  to  perform  periodic  follow-up
f  ACTH  levels  with  laboratory  tests  and  MRI  of  the  pituitary
land.  However,  other  non-speciﬁc  signs  associated  with  this
ase  could  beneﬁt  from  some  strategies  reported  in  the
iterature.7
Nelson’s  syndrome,  the  enlargement  of  an  autonomous
CTH-secreting  pituitary  adenoma,  is  a  typical  clinical  pre-
entation  following  bilateral  adrenalectomy  for  Cushing’s
yndrome,  and  would  explain  the  clinical  picture  following
utoimmune  adrenalitis  in  this  case.8 The  extended  timesagittal  and  coronal  plane.  Cold,  2.5  mm  lesion  located  in  the
apse  between  onset  of  symptoms  and  diagnosis  of  Addi-
on’s  disease  in  this  patient  could  have  caused  Nelson’s
yndrome,  as  during  this  period  ACTH  secretion  continued
nchecked  due  to  low  cortisol  levels.9,10 Although  many
ma  
R
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authors  suggest  that  this  is  not  such  a  rare  occurrence,  a
Medline  search  retrieved  only  1  article  speciﬁcally  analysing
this  problem.  For  this  reason,  we  have  decided  to  adopt  a
wait-and-see,  symptom-guided  approach  complemented  by
follow-up  campimetry  tests  and  imaging  studies.4
Another,  albeit  unlikely,  hypothesis  put  forward  to
explain  these  symptoms  is  non-adrenal  function-related
pituitary  ACTH  hypersecretion,  in  which  both  processes
would  have  developed  independently.
Treatment  strategies,  in  the  absence  of  evidence  of
any  other  hormonal  dysfunction  other  than  ACTH,  and  no
neurological  symptoms,  remain  unclear.6 However,  ACTH
hypersecretion  could  improve  with  replacement  therapies
aimed  at  improving  adrenal  hormone  homeostasis.11 This
approach  is  similar  to  that  taken  in  diabetes,  where  insulin
is  replaced  by  a  basal-bolus  regimen.
Conclusions
We  present  a  case  of  Addison’s  disease  treated  with  replace-
ment  therapy  that  actually  increased,  rather  than  reduced,
ACTH  levels.  Observing  rising  levels  over  time,  we  decided
to  perform  MRI  of  the  pituitary  gland,  which  showed  the
presence  of  a  microadenoma.  Various  hypotheses  have  been
put  forward  to  explain  this  phenomenon:
1.  Conventional  treatment  is  ineffective  in  inhibiting  ACTH
production.2.  The  pituitary  microadenoma  is  unrelated  to  Addison’s
disease  or  any  suprarenal  dysfunction.
3.  The  microadenoma  is  caused  by  an  autoimmune  adrenali-
tis,  and  symptomatology  is  similar  to  Nelson’s  syndrome.
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